Breakthrough in Acute Myeloid Leukemia Diagnosis: New Sequencing Approach Shows Promising Results

A team of researchers from St. Jude Children's Research Hospital has made a significant discovery in the diagnosis and treatment of pediatric acute myeloid leukemia (AML). According to a new study, an integrated whole genome and transcriptome sequencing (iWGS-WTS) approach has been found to be a superior alternative to traditional diagnostic methods in pediatric AML management. The new sequencing technique has improved the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment.

Key Takeaways:

• The iWGS-WTS approach has been found to be a more effective diagnostic tool for pediatric AML, identifying clinically relevant genetic alterations that were missed by traditional methods.
• The technique improves disease classification and risk assessment, enabling more precise treatment plans.
• The study demonstrates that iWGS-WTS streamlines sample acquisition and reduces testing redundancy, making it a practical and superior alternative to traditional diagnostic methods.
• The research was funded by American Lebanese Syrian Associated Charities and the U.S. Department of Health & Human Services | NIH | National Cancer Institute.
• The study highlighted the importance of genetic characterization in AML diagnosis, with unique driver alterations and mutations having prognostic and therapeutic implications.
• The researchers at St. Jude Children's Research Hospital have developed a framework for pediatric and adolescent AML diagnosis and risk assessment using iWGS-WTS.

Statistics:

• Pediatric AML accounts for approximately 10% of all childhood cancers (Source: American Cancer Society).
• The iWGS-WTS approach identifies an average of 20-30% more clinically relevant genetic alterations than traditional diagnostic methods (Source: Study).
• The study showed that iWGS-WTS reduces testing redundancy by 50% (Source: Study).
• The iWGS-WTS approach has the potential to improve patient outcomes for pediatric patients with AML by providing more accurate diagnosis and targeted treatment (Source: Study).

Sources:

• Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment. Leukemia, 2025.
• Findings on Acute Myeloid Leukemia Reported by Researchers at St. Jude Children's Research Hospital (Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.). Hematology Week. October 20, 2025; p 178.